Samenvatting:@0.147059:0.126494:0.288805:0.126494:0.288805:0.098384:0.147059:0.098384:0.011970:0.012318:0.017286:0.011069:0.013626:0.010836:0.011040:0.010343:0.010343:0.006217:0.013626:0.013074
Onderzoek  naar het  kanker  genoom is  dynamisch  en  gaat gepaard met  constante :@0.147059:0.168344:0.886500:0.168344:0.886500:0.147971:0.147059:0.147971:0.016298:0.011596:0.011322:0.009039:0.007807:0.008834:0.011276:0.008948:0.010523:0.004109:0.005216:0.011687:0.009382:0.009085:0.007807:0.009336:0.011299:0.009131:0.006437:0.004109:0.005216:0.010614:0.009085:0.011870:0.010272:0.009039:0.007807:0.004109:0.005216:0.009656:0.009039:0.011596:0.011276:0.010843:0.017645:0.009336:0.005615:0.007670:0.004109:0.005216:0.011322:0.009724:0.011687:0.009085:0.017645:0.005615:0.007875:0.008765:0.011459:0.004109:0.005216:0.009039:0.011756:0.004109:0.005216:0.009861:0.009382:0.008811:0.006437:0.009336:0.009656:0.009131:0.011365:0.009382:0.009087:0.007442:0.011391:0.009336:0.017485:0.009131:0.006437:0.004109:0.005216:0.008994:0.010843:0.011619:0.007510:0.006551:0.009085:0.011391:0.006211:0.009039:0.004109
vooruitgang op zowel methodologisch als technologisch vlak. Deze ontwikkelingen :@0.147059:0.188923:0.886389:0.188923:0.886389:0.168550:0.147059:0.168550:0.009633:0.011276:0.010843:0.007967:0.011413:0.005273:0.006437:0.009861:0.009085:0.011459:0.009861:0.008537:0.010820:0.011276:0.008537:0.008834:0.010863:0.014518:0.008948:0.005250:0.008537:0.017485:0.009131:0.006620:0.011299:0.011276:0.011322:0.010934:0.005182:0.011048:0.009861:0.005615:0.007875:0.008765:0.011459:0.008537:0.009405:0.005250:0.007670:0.008537:0.006209:0.009106:0.008765:0.011459:0.011598:0.010934:0.005182:0.011048:0.009861:0.005615:0.007873:0.008765:0.011459:0.008537:0.009907:0.005433:0.009405:0.010523:0.004497:0.008537:0.016228:0.009336:0.008834:0.009039:0.008537:0.010843:0.011391:0.006437:0.014723:0.005752:0.010888:0.010272:0.008948:0.005250:0.005615:0.011459:0.009656:0.009039:0.011756:0.004109
maken gepersonaliseerde en gerichte behandelingen voor kankerpatiënten mogelijk op :@0.147059:0.209502:0.886391:0.209502:0.886391:0.189129:0.147059:0.189129:0.017577:0.009405:0.010272:0.009039:0.011756:0.004862:0.009656:0.009131:0.011505:0.009039:0.007624:0.007873:0.010845:0.011687:0.009402:0.005250:0.005615:0.007875:0.009108:0.009039:0.007442:0.011322:0.009039:0.004862:0.009039:0.011756:0.004862:0.009656:0.009039:0.007807:0.005547:0.008765:0.011094:0.006209:0.009039:0.004862:0.011254:0.008948:0.011391:0.009085:0.011596:0.011322:0.008948:0.005250:0.005615:0.011459:0.009656:0.009039:0.011756:0.004862:0.009633:0.011276:0.010843:0.007807:0.004862:0.010614:0.009085:0.011870:0.010272:0.009039:0.007964:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006209:0.009039:0.011756:0.004862:0.017485:0.011048:0.009656:0.008948:0.005250:0.005273:0.005273:0.010523:0.004862:0.010820:0.011276:0.004109
basis van de unieke genomische profielen van tumoren. Voor dit proefschrift heb ik geb-:@0.147059:0.230080:0.882353:0.230080:0.882353:0.209707:0.147059:0.209707:0.011117:0.009291:0.007601:0.005615:0.007670:0.003881:0.009838:0.009085:0.011756:0.003881:0.011322:0.009039:0.003881:0.011413:0.011756:0.005547:0.008946:0.010274:0.009039:0.003881:0.009656:0.009039:0.011596:0.010843:0.017645:0.005615:0.007875:0.008765:0.011299:0.009039:0.003881:0.011071:0.007442:0.010843:0.005684:0.005615:0.008948:0.005182:0.009039:0.011756:0.003881:0.009838:0.009087:0.011756:0.003881:0.006163:0.011413:0.017485:0.010843:0.007442:0.009039:0.011756:0.004497:0.003881:0.012737:0.011276:0.010843:0.007807:0.003881:0.011391:0.005273:0.006437:0.003881:0.011071:0.007442:0.011276:0.009039:0.006072:0.007875:0.008765:0.011459:0.007807:0.005615:0.006197:0.006197:0.003881:0.011299:0.008902:0.011025:0.003881:0.005752:0.010523:0.003881:0.009656:0.008902:0.011089:0.007533
ruik gemaakt van nieuwe technologieën voor de verbetering van kankeronderzoek en :@0.147059:0.250659:0.886464:0.250659:0.886464:0.230286:0.147059:0.230286:0.007967:0.011413:0.005752:0.010523:0.005958:0.009656:0.009039:0.017577:0.009382:0.009405:0.010272:0.006437:0.005958:0.009838:0.009085:0.011756:0.005958:0.011756:0.005547:0.009131:0.011345:0.014518:0.009039:0.005958:0.006209:0.009108:0.008765:0.011459:0.011596:0.010934:0.005182:0.011048:0.009861:0.005547:0.009108:0.009039:0.011756:0.005958:0.009633:0.011276:0.010843:0.007807:0.005958:0.011322:0.009039:0.005958:0.009633:0.009039:0.007715:0.011251:0.009131:0.006211:0.009039:0.007807:0.005615:0.011457:0.009861:0.005958:0.009838:0.009085:0.011756:0.005958:0.010614:0.009087:0.011868:0.010274:0.009039:0.007442:0.010843:0.011596:0.011322:0.009039:0.007807:0.008834:0.011274:0.008950:0.010523:0.005958:0.009039:0.011756:0.004109
-zorg. In :@0.147059:0.271238:0.224373:0.271238:0.224373:0.250865:0.147059:0.250865:0.007533:0.008834:0.010843:0.007624:0.009679:0.004497:0.005547:0.006894:0.011756:0.004109
hoofdstuk 1:@0.225805:0.271238:0.333305:0.271238:0.333305:0.250105:0.225805:0.250105:0.011779:0.011756:0.011322:0.006391:0.011801:0.008035:0.006825:0.012096:0.011162:0.005421:0.010911
 heb ik de verschillende soorten genomische variatie, de genom-:@0.333306:0.271238:0.882353:0.271238:0.882353:0.250865:0.333306:0.250865:0.005547:0.011299:0.008902:0.011025:0.005547:0.005752:0.010523:0.005547:0.011322:0.009039:0.005547:0.009633:0.009039:0.007624:0.007875:0.008763:0.011459:0.005752:0.005387:0.005182:0.009039:0.011596:0.011322:0.009039:0.005547:0.007875:0.011276:0.010843:0.007967:0.006209:0.009039:0.011756:0.005547:0.009656:0.009039:0.011598:0.010840:0.017645:0.005615:0.007875:0.008765:0.011299:0.009039:0.005547:0.009838:0.009085:0.007807:0.005798:0.008811:0.006437:0.005547:0.008743:0.004497:0.005547:0.011324:0.009039:0.005547:0.009656:0.009039:0.011596:0.010843:0.017617:0.007533
ische kenmerken van kanker, het belang van genomische technologie voor gepersonali-:@0.147059:0.291816:0.882353:0.291816:0.882353:0.271444:0.147059:0.271444:0.005615:0.007875:0.008765:0.011299:0.009039:0.004565:0.010272:0.009039:0.011756:0.017485:0.009039:0.007601:0.010272:0.009039:0.011756:0.004565:0.009838:0.009085:0.011756:0.004565:0.010614:0.009085:0.011870:0.010272:0.009039:0.006255:0.004497:0.004565:0.011299:0.009131:0.006437:0.004565:0.011251:0.008950:0.005430:0.009085:0.011461:0.009861:0.004565:0.009838:0.009085:0.011756:0.004565:0.009653:0.009039:0.011598:0.010843:0.017645:0.005615:0.007873:0.008765:0.011299:0.009039:0.004565:0.006209:0.009108:0.008765:0.011459:0.011596:0.010934:0.005182:0.011048:0.009861:0.005547:0.009039:0.004565:0.009633:0.011276:0.010843:0.007807:0.004565:0.009656:0.009131:0.011505:0.009039:0.007624:0.007875:0.010843:0.011687:0.009405:0.005250:0.005661:0.007533
seerde geneeskunde en het potentieel van vloeibare biopsieën voor minimaal invasieve :@0.147059:0.312395:0.886482:0.312395:0.886482:0.292022:0.147059:0.292022:0.007875:0.009108:0.009039:0.007442:0.011322:0.009039:0.005113:0.009656:0.009039:0.011596:0.009108:0.009039:0.007556:0.010272:0.011413:0.011596:0.011322:0.009039:0.005113:0.009039:0.011756:0.005113:0.011299:0.009131:0.006437:0.005113:0.011505:0.010820:0.006209:0.009039:0.011391:0.006437:0.005547:0.009108:0.008948:0.005250:0.005113:0.009838:0.009085:0.011756:0.005113:0.009905:0.005182:0.011276:0.009039:0.005547:0.011117:0.009085:0.007442:0.009039:0.005113:0.010820:0.005547:0.010820:0.011185:0.007601:0.005547:0.009108:0.009039:0.011756:0.005113:0.009633:0.011276:0.010843:0.007807:0.005113:0.017645:0.005615:0.011756:0.005615:0.017577:0.009382:0.009402:0.005250:0.005113:0.005615:0.011368:0.009838:0.009291:0.007601:0.005547:0.009336:0.009633:0.009039:0.004109
kankermonitoring geïntroduceerd. Daarnaast heb ik modelsystemen geïntroduceerd :@0.147059:0.332974:0.886489:0.332974:0.886489:0.312601:0.147059:0.312601:0.010614:0.009085:0.011870:0.010272:0.009039:0.007807:0.017485:0.010843:0.011756:0.005273:0.006209:0.010843:0.007807:0.005615:0.011459:0.009861:0.008286:0.009656:0.009039:0.005615:0.011391:0.006437:0.007442:0.011276:0.011048:0.011345:0.008994:0.009108:0.009039:0.007442:0.011117:0.004497:0.008286:0.016207:0.009382:0.009085:0.007807:0.011687:0.009382:0.009291:0.007510:0.006437:0.008286:0.011302:0.008902:0.011025:0.008286:0.005752:0.010523:0.008286:0.017485:0.011276:0.011322:0.008948:0.005250:0.007761:0.009724:0.007510:0.006209:0.009039:0.017485:0.009039:0.011756:0.008286:0.009656:0.009039:0.005615:0.011391:0.006437:0.007442:0.011276:0.011048:0.011345:0.008994:0.009108:0.009039:0.007442:0.011391:0.004109
die  worden  gebruikt  bij  kankeronderzoek,  waaronder  PDO's  (patiënt-afgeleide  or-:@0.147059:0.353553:0.882353:0.353553:0.882353:0.333180:0.147059:0.333180:0.011391:0.005547:0.009039:0.004109:0.005764:0.014518:0.010843:0.007442:0.011322:0.009039:0.011756:0.004109:0.005764:0.009656:0.008902:0.010820:0.007967:0.011413:0.005752:0.010272:0.006437:0.004109:0.005764:0.010820:0.005271:0.005273:0.004109:0.005764:0.010614:0.009085:0.011870:0.010274:0.009039:0.007442:0.010843:0.011598:0.011322:0.009039:0.007807:0.008834:0.011274:0.008948:0.010523:0.004497:0.004109:0.005764:0.014723:0.009382:0.009085:0.007442:0.010843:0.011596:0.011322:0.009039:0.007807:0.004109:0.005764:0.011664:0.016504:0.016412:0.003196:0.007670:0.004109:0.005764:0.006939:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.007533:0.009085:0.006209:0.009658:0.008948:0.005182:0.009039:0.005547:0.011320:0.009039:0.004109:0.005764:0.010843:0.007234:0.007533
ganoïden), waarin het potentieel voor hun gebruik, met name bij eierstokkanker wordt :@0.147059:0.374131:0.886464:0.374131:0.886464:0.353758:0.147059:0.353758:0.009861:0.009085:0.011596:0.010843:0.005547:0.011322:0.009039:0.011756:0.006939:0.004497:0.004953:0.014723:0.009382:0.009085:0.007807:0.005615:0.011756:0.004953:0.011299:0.009131:0.006437:0.004953:0.011502:0.010820:0.006209:0.009039:0.011391:0.006437:0.005547:0.009108:0.008948:0.005250:0.004953:0.009633:0.011276:0.010843:0.007807:0.004953:0.011094:0.011413:0.011756:0.004953:0.009656:0.008902:0.010820:0.007967:0.011413:0.005752:0.010523:0.004497:0.004953:0.017485:0.009131:0.006437:0.004953:0.011687:0.009085:0.017485:0.009039:0.004953:0.010820:0.005273:0.005273:0.004953:0.009039:0.005547:0.009039:0.007624:0.007512:0.006209:0.010934:0.010888:0.010612:0.009087:0.011870:0.010272:0.009039:0.007807:0.004953:0.014518:0.010843:0.007442:0.011048:0.006437:0.004109
beschreven. Ten slotte heb ik de rol van somatische structurele variaties (SVs) bij kanker :@0.147059:0.394710:0.886484:0.394710:0.886484:0.374337:0.147059:0.374337:0.011254:0.009039:0.007875:0.008765:0.011459:0.007442:0.009336:0.009633:0.009039:0.011756:0.004497:0.004223:0.010866:0.009039:0.011756:0.004223:0.007556:0.005182:0.010820:0.006163:0.006209:0.009039:0.004223:0.011299:0.008902:0.011025:0.004223:0.005752:0.010523:0.004223:0.011322:0.009039:0.004223:0.007442:0.010934:0.005250:0.004223:0.009838:0.009085:0.011756:0.004223:0.007875:0.010843:0.017577:0.008811:0.006437:0.005615:0.007875:0.008765:0.011299:0.009039:0.004223:0.007510:0.006437:0.007967:0.011345:0.009108:0.006163:0.011413:0.007442:0.008948:0.005182:0.009039:0.004223:0.009838:0.009085:0.007807:0.005796:0.008811:0.006437:0.005547:0.009039:0.007670:0.004223:0.006939:0.010112:0.015089:0.007670:0.006939:0.004223:0.010820:0.005273:0.005273:0.004223:0.010614:0.009085:0.011870:0.010272:0.009039:0.007807:0.004109
geïntroduceerd en de verschillende  sequencing technieken die worden gebruikt om ze :@0.147059:0.415289:0.886441:0.415289:0.886441:0.394916:0.147059:0.394916:0.009656:0.009039:0.005615:0.011391:0.006437:0.007442:0.011276:0.011048:0.011345:0.008994:0.009108:0.009039:0.007442:0.011391:0.005113:0.009039:0.011756:0.005113:0.011322:0.009039:0.005113:0.009633:0.009039:0.007624:0.007875:0.008765:0.011459:0.005752:0.005387:0.005182:0.009039:0.011596:0.011322:0.009039:0.005113:0.005113:0.007875:0.009106:0.010706:0.011345:0.009039:0.011598:0.008994:0.005615:0.011459:0.009861:0.005113:0.006209:0.009108:0.008765:0.011459:0.011756:0.005547:0.008948:0.010272:0.009039:0.011756:0.005113:0.011391:0.005547:0.009039:0.005113:0.014518:0.010843:0.007442:0.011322:0.009039:0.011756:0.005113:0.009656:0.008902:0.010820:0.007967:0.011413:0.005750:0.010274:0.006437:0.005113:0.010843:0.017645:0.005113:0.008834:0.009039:0.004109
te detecteren, samen met de uitdagingen die dit met zich meebrengt. :@0.147059:0.435867:0.721924:0.435867:0.721924:0.415494:0.147059:0.415494:0.006209:0.009039:0.004109:0.011322:0.009131:0.006209:0.009108:0.009108:0.006209:0.009039:0.007442:0.009039:0.011756:0.004497:0.004109:0.007941:0.009085:0.017488:0.009039:0.011756:0.004109:0.017485:0.009128:0.006437:0.004109:0.011322:0.009039:0.004109:0.011413:0.005273:0.006209:0.011573:0.009199:0.009861:0.005615:0.011459:0.009656:0.009039:0.011756:0.004109:0.011391:0.005547:0.009039:0.004109:0.011391:0.005273:0.006437:0.004109:0.017483:0.009131:0.006437:0.004109:0.008834:0.005547:0.008765:0.011459:0.004109:0.017485:0.009108:0.008902:0.010820:0.007442:0.009039:0.011459:0.009861:0.006437:0.004497:0.004109
In het eerste deel van dit proefschrift hebben we organoïden technologie gebruikt om :@0.147059:0.477025:0.886368:0.477025:0.886368:0.456652:0.147059:0.456652:0.006894:0.011756:0.005935:0.011299:0.009131:0.006437:0.005935:0.009108:0.009039:0.007624:0.007510:0.006209:0.009039:0.005935:0.011322:0.009108:0.008948:0.005250:0.005935:0.009838:0.009085:0.011756:0.005935:0.011391:0.005273:0.006437:0.005935:0.011071:0.007442:0.011274:0.009039:0.006072:0.007875:0.008765:0.011459:0.007807:0.005615:0.006197:0.006197:0.005935:0.011302:0.008900:0.010934:0.011254:0.009039:0.011756:0.005935:0.014518:0.009039:0.005935:0.010843:0.007624:0.009861:0.009085:0.011596:0.010843:0.005547:0.011322:0.009039:0.011756:0.005935:0.006209:0.009108:0.008765:0.011459:0.011596:0.010934:0.005182:0.011048:0.009861:0.005547:0.009039:0.005935:0.009656:0.008902:0.010820:0.007964:0.011413:0.005752:0.010272:0.006437:0.005935:0.010843:0.017645:0.004109
onderzoek naar eierstokkanker te bevorderen. In :@0.147059:0.497603:0.578074:0.497603:0.578074:0.477231:0.147059:0.477231:0.010843:0.011596:0.011322:0.009039:0.007807:0.008834:0.011276:0.008948:0.010523:0.007556:0.011687:0.009382:0.009085:0.007807:0.007556:0.009039:0.005547:0.009039:0.007624:0.007510:0.006209:0.010934:0.010888:0.010614:0.009085:0.011870:0.010272:0.009039:0.007807:0.007556:0.006209:0.009039:0.007556:0.011254:0.009334:0.009635:0.010843:0.007442:0.011322:0.009039:0.007442:0.009039:0.011756:0.004497:0.007556:0.006894:0.011756:0.004109
hoofdstuk 2:@0.581475:0.497603:0.690927:0.497603:0.690927:0.476471:0.581475:0.476471:0.011779:0.011756:0.011322:0.006391:0.011801:0.008035:0.006825:0.012096:0.011162:0.007373:0.010911
 hebben we een PDO :@0.690936:0.497603:0.886491:0.497603:0.886491:0.477231:0.690936:0.477231:0.007556:0.011299:0.008902:0.010934:0.011251:0.009039:0.011756:0.007556:0.014518:0.009039:0.007556:0.009108:0.009039:0.011756:0.007556:0.011664:0.016504:0.016412:0.004109
biobank opgezet en de toepassingen ervan gepresenteerd. De biobank bestond uit 56 :@0.147059:0.518182:0.886414:0.518182:0.886414:0.497809:0.147059:0.497809:0.010820:0.005547:0.010957:0.011117:0.009085:0.011870:0.010523:0.006506:0.010820:0.011276:0.009656:0.009334:0.008834:0.009131:0.006437:0.006506:0.009039:0.011756:0.006506:0.011322:0.009039:0.006506:0.006209:0.011276:0.009131:0.011368:0.009291:0.007533:0.007601:0.005615:0.011459:0.009656:0.009039:0.011756:0.006506:0.009039:0.008400:0.009838:0.009085:0.011756:0.006506:0.009656:0.009131:0.011071:0.007442:0.009039:0.007875:0.009039:0.011391:0.006209:0.009106:0.009039:0.007442:0.011117:0.004497:0.006506:0.016230:0.009039:0.006506:0.010820:0.005547:0.010957:0.011117:0.009085:0.011870:0.010523:0.006506:0.011254:0.009039:0.007510:0.006209:0.010843:0.011596:0.011391:0.006506:0.011413:0.005273:0.006437:0.006506:0.010432:0.010432:0.004109
PDO-lijnen van 32  patiënten en omvatte alle belangrijke histologische subtypes van :@0.147059:0.538761:0.886544:0.538761:0.886544:0.518388:0.147059:0.518388:0.011664:0.016504:0.016412:0.007533:0.005250:0.005271:0.005273:0.011596:0.009039:0.011756:0.007715:0.009838:0.009087:0.011756:0.007715:0.010432:0.010432:0.004109:0.003595:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006209:0.009039:0.011756:0.007715:0.009039:0.011756:0.007715:0.010843:0.017257:0.009838:0.008811:0.006163:0.006209:0.009039:0.007715:0.009405:0.005387:0.005182:0.009039:0.007715:0.011254:0.008948:0.005433:0.009085:0.011459:0.009861:0.007807:0.005273:0.005273:0.010272:0.009039:0.007715:0.011459:0.005615:0.007510:0.006209:0.010934:0.005182:0.011048:0.009861:0.005615:0.007875:0.008765:0.011299:0.009039:0.007715:0.007512:0.011345:0.010797:0.006437:0.009724:0.011502:0.009039:0.007670:0.007715:0.009838:0.009085:0.011756:0.004109
eierstokkanker. We hebben de organoïde lijnen gekarakteriseerd op histopathologisch, :@0.147059:0.559340:0.886507:0.559340:0.886507:0.538967:0.147059:0.538967:0.009039:0.005547:0.009039:0.007624:0.007510:0.006209:0.010934:0.010888:0.010614:0.009085:0.011870:0.010272:0.009039:0.006255:0.004497:0.005661:0.018649:0.009039:0.005661:0.011299:0.008902:0.010934:0.011254:0.009039:0.011756:0.005661:0.011322:0.009039:0.005661:0.010843:0.007624:0.009861:0.009085:0.011596:0.010843:0.005547:0.011322:0.009039:0.005661:0.005250:0.005273:0.005273:0.011596:0.009039:0.011756:0.005661:0.009656:0.008948:0.010614:0.009085:0.007898:0.009405:0.010272:0.006209:0.009039:0.007807:0.005615:0.007875:0.009108:0.009039:0.007442:0.011391:0.005661:0.010820:0.011276:0.005661:0.011459:0.005615:0.007510:0.006209:0.010820:0.011368:0.008811:0.006620:0.011299:0.010934:0.005182:0.011048:0.009861:0.005615:0.007873:0.008765:0.011459:0.004497:0.004109
genomisch en epigenomisch niveau en lieten zien hoe deze lijnen nauwgezet de oor-:@0.147059:0.579918:0.882353:0.579918:0.882353:0.559545:0.147059:0.559545:0.009656:0.009039:0.011596:0.010843:0.017645:0.005615:0.007875:0.008765:0.011459:0.006574:0.009039:0.011756:0.006574:0.009131:0.011071:0.005615:0.009656:0.009039:0.011596:0.010843:0.017645:0.005615:0.007875:0.008765:0.011459:0.006574:0.011756:0.005547:0.009633:0.009288:0.008813:0.011413:0.006574:0.009039:0.011756:0.006574:0.005250:0.005547:0.009128:0.006211:0.009039:0.011756:0.006574:0.008834:0.005545:0.009039:0.011756:0.006574:0.011302:0.011274:0.009039:0.006574:0.011322:0.009336:0.008834:0.009039:0.006574:0.005250:0.005273:0.005273:0.011596:0.009039:0.011756:0.006574:0.011687:0.008811:0.011345:0.014632:0.009656:0.009336:0.008834:0.009131:0.006437:0.006574:0.011322:0.009039:0.006574:0.011276:0.010843:0.007236:0.007533
spronkelijke tumoren nabootsten. We hebben ook aangetoond dat deze kenmerken na :@0.147059:0.600497:0.886464:0.600497:0.886464:0.580124:0.147059:0.580124:0.007510:0.011071:0.007442:0.010843:0.011870:0.010272:0.008948:0.005250:0.005273:0.005273:0.010272:0.009039:0.005227:0.006163:0.011413:0.017485:0.010843:0.007442:0.009039:0.011756:0.005227:0.011687:0.009108:0.011254:0.011276:0.010820:0.006437:0.007510:0.006209:0.009039:0.011756:0.004497:0.005227:0.018649:0.009039:0.005227:0.011299:0.008902:0.010934:0.011254:0.009039:0.011756:0.005227:0.011274:0.010934:0.010523:0.005227:0.009382:0.009085:0.011459:0.009658:0.009128:0.006211:0.011274:0.010843:0.011598:0.011391:0.005227:0.011573:0.008811:0.006437:0.005227:0.011322:0.009336:0.008834:0.009039:0.005227:0.010272:0.009039:0.011756:0.017485:0.009039:0.007601:0.010272:0.009039:0.011756:0.005227:0.011687:0.009291:0.004109
langdurige kweek behouden bleven. Verder toonde analyse van het transcriptoom aan :@0.147059:0.621076:0.886441:0.621076:0.886441:0.600703:0.147059:0.600703:0.005433:0.009085:0.011459:0.009656:0.011048:0.011413:0.007807:0.005615:0.009656:0.009039:0.005593:0.010455:0.014518:0.009108:0.008948:0.010523:0.005593:0.011254:0.008948:0.011299:0.010820:0.011345:0.011322:0.009039:0.011756:0.005593:0.010911:0.005182:0.009336:0.009633:0.009039:0.011756:0.004497:0.005593:0.012737:0.009039:0.007442:0.011322:0.009039:0.007807:0.005593:0.006209:0.011276:0.010843:0.011596:0.011322:0.009039:0.005593:0.009085:0.011687:0.009405:0.005182:0.009724:0.007875:0.009039:0.005593:0.009838:0.009085:0.011756:0.005593:0.011299:0.009131:0.006437:0.005593:0.006437:0.007898:0.009085:0.011619:0.007875:0.008994:0.007807:0.005273:0.011048:0.006209:0.011276:0.010843:0.017645:0.005593:0.009382:0.009085:0.011756:0.004109
dat de PDO-lijnen van de verschillende subtypen van eierstokkanker samen clusteren :@0.147059:0.641654:0.886416:0.641654:0.886416:0.621281:0.147059:0.621281:0.011573:0.008811:0.006437:0.005935:0.011322:0.009039:0.005935:0.011664:0.016504:0.016412:0.007533:0.005250:0.005271:0.005273:0.011596:0.009039:0.011756:0.005935:0.009838:0.009085:0.011756:0.005935:0.011322:0.009039:0.005935:0.009633:0.009039:0.007624:0.007875:0.008765:0.011459:0.005752:0.005387:0.005182:0.009039:0.011596:0.011322:0.009039:0.005935:0.007510:0.011345:0.010797:0.006437:0.009724:0.011505:0.009039:0.011756:0.005935:0.009838:0.009085:0.011756:0.005935:0.009039:0.005547:0.009039:0.007624:0.007510:0.006209:0.010934:0.010888:0.010614:0.009085:0.011870:0.010272:0.009039:0.007807:0.005935:0.007941:0.009087:0.017485:0.009039:0.011756:0.005935:0.008765:0.004905:0.011413:0.007512:0.006209:0.009039:0.007442:0.009039:0.011756:0.004109
op basis van expressiepatronen. Ook was de heterogeniteit binnen en tussen patiënten :@0.147059:0.662233:0.886462:0.662233:0.886462:0.641860:0.147059:0.641860:0.010820:0.011276:0.005570:0.011117:0.009291:0.007601:0.005615:0.007670:0.005570:0.009838:0.009085:0.011756:0.005570:0.009108:0.010089:0.011071:0.007442:0.009039:0.007533:0.007601:0.005547:0.009131:0.011368:0.008809:0.006437:0.007442:0.010845:0.011596:0.009039:0.011756:0.004497:0.005570:0.016504:0.010934:0.010523:0.005570:0.014723:0.009291:0.007670:0.005570:0.011322:0.009039:0.005570:0.011299:0.009131:0.006209:0.009039:0.007442:0.011048:0.009656:0.009039:0.011756:0.005273:0.006209:0.009039:0.005271:0.006437:0.005570:0.010820:0.005615:0.011756:0.011598:0.009039:0.011756:0.005570:0.009039:0.011756:0.005570:0.006163:0.011413:0.007533:0.007875:0.009039:0.011756:0.005570:0.011365:0.008811:0.006437:0.005547:0.009039:0.011391:0.006209:0.009039:0.011756:0.004109
vertegenwoordigd in de biobank. We presenteerden tevens een proof-of-concept voor :@0.147059:0.682812:0.886414:0.682812:0.886414:0.662439:0.147059:0.662439:0.009633:0.009039:0.007967:0.006209:0.009039:0.009656:0.009039:0.011368:0.014518:0.011276:0.010843:0.007442:0.011391:0.005615:0.009656:0.011391:0.005844:0.005615:0.011756:0.005844:0.011322:0.009039:0.005844:0.010820:0.005547:0.010957:0.011117:0.009085:0.011870:0.010523:0.004497:0.005844:0.018649:0.009039:0.005844:0.011071:0.007442:0.009039:0.007875:0.009039:0.011391:0.006209:0.009108:0.009039:0.007442:0.011322:0.009039:0.011756:0.005844:0.006209:0.009334:0.009633:0.009039:0.011619:0.007670:0.005844:0.009106:0.009039:0.011756:0.005844:0.011071:0.007442:0.011276:0.010843:0.006209:0.007533:0.010840:0.006209:0.007533:0.008994:0.010843:0.011596:0.008994:0.009131:0.011048:0.006437:0.005844:0.009635:0.011274:0.010845:0.007807:0.004109
drug screeningsonderzoeken op deze PDO’s met verschillende subtype-reacties op pla-:@0.147059:0.703390:0.882353:0.703390:0.882353:0.683018:0.147059:0.683018:0.011391:0.007967:0.011413:0.009861:0.004862:0.007875:0.008994:0.007442:0.009108:0.009039:0.011756:0.005615:0.011459:0.009722:0.007875:0.010845:0.011596:0.011322:0.009039:0.007807:0.008834:0.011274:0.008948:0.010272:0.009039:0.011756:0.004862:0.010820:0.011276:0.004862:0.011322:0.009336:0.008834:0.009039:0.004862:0.011664:0.016504:0.015089:0.001735:0.007670:0.004862:0.017485:0.009131:0.006437:0.004862:0.009633:0.009039:0.007624:0.007875:0.008765:0.011459:0.005752:0.005387:0.005182:0.009039:0.011596:0.011322:0.009039:0.004862:0.007510:0.011345:0.010797:0.006437:0.009724:0.011505:0.009039:0.007533:0.007442:0.009291:0.009291:0.009108:0.006437:0.005547:0.009039:0.007670:0.004862:0.010820:0.011276:0.004862:0.011162:0.005433:0.009291:0.007533
tina-bevattende chemotherapie. Resistentie tegen chemotherapie bij recidief kwam ook :@0.147059:0.723969:0.886468:0.723969:0.886468:0.703596:0.147059:0.703596:0.006437:0.005615:0.011687:0.009291:0.007533:0.011254:0.009334:0.009838:0.008811:0.006166:0.006209:0.009039:0.011596:0.011322:0.009039:0.004794:0.008765:0.011299:0.009039:0.017485:0.010820:0.006620:0.011299:0.009039:0.007898:0.008811:0.011071:0.005547:0.008743:0.004497:0.004794:0.013694:0.009039:0.007604:0.005615:0.007510:0.006209:0.009039:0.011391:0.006437:0.005547:0.009039:0.004794:0.006211:0.009039:0.009656:0.009039:0.011756:0.004794:0.008768:0.011299:0.009039:0.017485:0.010820:0.006620:0.011299:0.009039:0.007898:0.008811:0.011071:0.005547:0.009039:0.004794:0.010820:0.005273:0.005273:0.004794:0.007442:0.009108:0.008994:0.005547:0.011391:0.005547:0.009039:0.006209:0.004794:0.010455:0.014723:0.009085:0.017645:0.004794:0.011276:0.010934:0.010523:0.004109
tot uiting in de biobank. Ten slotte hebben we aangetoond dat de PDO's konden worden :@0.147059:0.744548:0.886462:0.744548:0.886462:0.724175:0.147059:0.724175:0.006209:0.010820:0.006437:0.003846:0.011413:0.005273:0.006437:0.005615:0.011459:0.009861:0.003846:0.005615:0.011756:0.003846:0.011322:0.009039:0.003846:0.010820:0.005547:0.010955:0.011117:0.009087:0.011868:0.010523:0.004497:0.003846:0.010866:0.009039:0.011756:0.003846:0.007556:0.005182:0.010820:0.006163:0.006209:0.009039:0.003846:0.011299:0.008902:0.010934:0.011254:0.009039:0.011756:0.003846:0.014518:0.009039:0.003846:0.009382:0.009085:0.011459:0.009656:0.009131:0.006209:0.011276:0.010843:0.011596:0.011391:0.003846:0.011573:0.008811:0.006437:0.003846:0.011322:0.009039:0.003846:0.011664:0.016504:0.016412:0.003196:0.007670:0.003846:0.010272:0.010843:0.011596:0.011322:0.009039:0.011756:0.003846:0.014518:0.010843:0.007442:0.011322:0.009039:0.011756:0.004109
getransplanteerd in muizen voor in vivo medicatie gevoeligheids assays en dat PDO's :@0.147059:0.765127:0.886498:0.765127:0.886498:0.744754:0.147059:0.744754:0.009656:0.009131:0.006437:0.007898:0.009085:0.011619:0.007510:0.011162:0.005433:0.009085:0.011391:0.006209:0.009108:0.009039:0.007442:0.011391:0.006209:0.005615:0.011756:0.006197:0.017280:0.011413:0.005615:0.008834:0.009039:0.011756:0.006197:0.009633:0.011276:0.010843:0.007807:0.006209:0.005615:0.011756:0.006197:0.009838:0.005547:0.009635:0.011048:0.006197:0.017485:0.009108:0.011391:0.005547:0.009108:0.008811:0.006437:0.005547:0.009039:0.006197:0.009656:0.009336:0.009633:0.011276:0.008948:0.005250:0.005615:0.009930:0.011299:0.009039:0.005547:0.011391:0.007670:0.006197:0.009291:0.007533:0.007944:0.008925:0.009724:0.007670:0.006209:0.009039:0.011756:0.006197:0.011573:0.008811:0.006437:0.006209:0.011664:0.016501:0.016412:0.003196:0.007670:0.004109
bruikbaar waren voor genetische modificatie voor onderzoek naar tumorgenese. Onze :@0.147059:0.785705:0.886532:0.785705:0.886532:0.765332:0.147059:0.765332:0.010820:0.007967:0.011413:0.005752:0.010272:0.011117:0.009382:0.009085:0.007807:0.005341:0.014723:0.009085:0.007442:0.009039:0.011756:0.005341:0.009633:0.011276:0.010843:0.007807:0.005341:0.009656:0.009039:0.011596:0.009131:0.006437:0.005615:0.007873:0.008765:0.011302:0.009039:0.005341:0.017485:0.011276:0.011391:0.005615:0.005684:0.005615:0.009108:0.008811:0.006437:0.005547:0.009039:0.005341:0.009633:0.011276:0.010843:0.007807:0.005341:0.010843:0.011596:0.011322:0.009039:0.007807:0.008834:0.011276:0.008948:0.010523:0.005341:0.011687:0.009382:0.009085:0.007807:0.005341:0.006163:0.011413:0.017485:0.010843:0.007624:0.009656:0.009039:0.011596:0.009039:0.007875:0.008743:0.004497:0.005341:0.016298:0.011756:0.008834:0.009039:0.004109
resultaten tonen het potentieel van organoïden om eierstokkankeronderzoek te bevor-:@0.147059:0.806284:0.882353:0.806284:0.882353:0.785911:0.147059:0.785911:0.007442:0.009039:0.007510:0.011550:0.004908:0.006551:0.008811:0.006209:0.009039:0.011756:0.005433:0.006209:0.010843:0.011596:0.009039:0.011756:0.005433:0.011302:0.009131:0.006437:0.005433:0.011505:0.010820:0.006209:0.009039:0.011391:0.006437:0.005547:0.009108:0.008948:0.005250:0.005433:0.009838:0.009085:0.011756:0.005433:0.010843:0.007624:0.009861:0.009085:0.011598:0.010843:0.005547:0.011322:0.009039:0.011756:0.005433:0.010843:0.017645:0.005433:0.009039:0.005547:0.009039:0.007624:0.007510:0.006209:0.010934:0.010888:0.010614:0.009085:0.011870:0.010272:0.009039:0.007442:0.010843:0.011596:0.011322:0.009039:0.007807:0.008834:0.011276:0.008948:0.010523:0.005433:0.006209:0.009039:0.005433:0.011254:0.009336:0.009633:0.010843:0.007184:0.007533
deren.:@0.147059:0.826863:0.200154:0.826863:0.200154:0.806490:0.147059:0.806490:0.011322:0.009039:0.007442:0.009039:0.011756:0.004497
In :@0.147059:0.868020:0.169817:0.868020:0.169817:0.847647:0.147059:0.847647:0.006894:0.011756:0.004109
hoofdstuk 3:@0.169891:0.868020:0.276056:0.868020:0.276056:0.846887:0.169891:0.846887:0.011779:0.011756:0.011322:0.006391:0.011801:0.008035:0.006825:0.012096:0.011162:0.004086:0.010911
 hebben we de PDO biobank van eierstokkanker uitgebreid en de PDO's :@0.276061:0.868020:0.886401:0.868020:0.886401:0.847647:0.276061:0.847647:0.004177:0.011299:0.008902:0.010934:0.011254:0.009039:0.011756:0.004177:0.014518:0.009039:0.004177:0.011322:0.009039:0.004177:0.011664:0.016504:0.016412:0.004177:0.010820:0.005547:0.010957:0.011117:0.009085:0.011870:0.010523:0.004177:0.009838:0.009085:0.011756:0.004177:0.009039:0.005547:0.009039:0.007624:0.007510:0.006209:0.010934:0.010888:0.010614:0.009085:0.011870:0.010272:0.009039:0.007807:0.004177:0.011413:0.005273:0.006437:0.009656:0.008902:0.010820:0.007442:0.009039:0.005547:0.011391:0.004177:0.009039:0.011756:0.004177:0.011320:0.009039:0.004177:0.011664:0.016504:0.016412:0.003196:0.007670:0.004109
gebruikt voor uitgebreide drugsscreening. We hebben screenings uitgevoerd op 36 :@0.147059:0.888599:0.886530:0.888599:0.886530:0.868226:0.147059:0.868226:0.009656:0.008902:0.010820:0.007967:0.011413:0.005752:0.010272:0.006437:0.009199:0.009635:0.011274:0.010845:0.007807:0.009199:0.011413:0.005273:0.006437:0.009656:0.008902:0.010820:0.007442:0.009039:0.005547:0.011322:0.009039:0.009199:0.011391:0.007967:0.011413:0.009724:0.007533:0.007873:0.008994:0.007442:0.009108:0.009039:0.011756:0.005615:0.011459:0.009679:0.004497:0.009199:0.018649:0.009039:0.009199:0.011299:0.008902:0.010934:0.011251:0.009039:0.011756:0.009199:0.007875:0.008994:0.007442:0.009108:0.009039:0.011756:0.005615:0.011459:0.009724:0.007670:0.009199:0.011413:0.005273:0.006437:0.009656:0.009336:0.009633:0.011276:0.009039:0.007442:0.011391:0.009199:0.010820:0.011276:0.009199:0.010432:0.010432:0.004109
PDO-lijnen die zijn afgeleid van 23 patiënten en we hebben retrospectief de reactie van :@0.147059:0.909178:0.886503:0.909178:0.886503:0.888805:0.147059:0.888805:0.011664:0.016504:0.016412:0.007533:0.005250:0.005271:0.005273:0.011596:0.009039:0.011756:0.004702:0.011391:0.005547:0.009039:0.004702:0.008834:0.005273:0.005273:0.011756:0.004702:0.009085:0.006209:0.009656:0.008948:0.005182:0.009039:0.005547:0.011391:0.004702:0.009838:0.009085:0.011756:0.004702:0.010432:0.010432:0.004702:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006209:0.009039:0.011756:0.004702:0.009039:0.011756:0.004702:0.014518:0.009039:0.004702:0.011299:0.008902:0.010932:0.011254:0.009039:0.011756:0.004702:0.007442:0.009131:0.006437:0.007442:0.010957:0.007510:0.011505:0.009108:0.009106:0.006437:0.005547:0.009039:0.006209:0.004702:0.011322:0.009039:0.004702:0.007442:0.009291:0.009291:0.009108:0.006437:0.005547:0.009039:0.004702:0.009838:0.009085:0.011756:0.004109
211:@0.890196:0.957873:0.913516:0.957873:0.913516:0.938882:0.890196:0.938882:0.007923:0.006807:0.008591
SAMENVATTING:@0.772374:0.066557:0.882354:0.066557:0.882354:0.045634:0.772374:0.045634:0.009405:0.009679:0.013582:0.008537:0.010706:0.008514:0.008674:0.007807:0.007807:0.004291:0.010706:0.010272